Trial Profile
Phase I trial of AZP 2006 in healthy volunteers after single administration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2015
Price :
$35
*
At a glance
- Drugs Ezeprogind (Primary)
- Indications Alzheimer's disease; Dementia; Progressive supranuclear palsy
- Focus Adverse reactions; First in man
- Sponsors AlzProtect
- 21 Oct 2014 New trial record
- 17 Sep 2014 Status changed from planning to recruiting, according to an AlzProtect media release.